Table 1.
Approach | Cell type specificity | Principle | Advantages | Limitations | Reference |
---|---|---|---|---|---|
(a) Transplantation models | |||||
BMT; TBI | BMDM | HSC source of blood monocytes is replaced with modified/labeled HSCs | High chimerism No time consuming crossing into genetic disease models |
Variability in myeloablation and reconstitution Artificial engraftment of BM cells in the CNS |
(113) |
BMT; HPI | BMDM | HSC source of blood monocytes is replaced with modified/labeled HSCs | High chimerism No time consuming crossing into genetic disease models |
Variability in myelo-ablation and reconstitution | (37, 113) |
BMT; Busulfan | BMDM | HSC source of blood monocytes is replaced with modified/labeled HSCs | High chimerism No time consuming crossing into genetic disease modelsChemical myeloablation No irradiation |
Variability in myeloablation and reconstitution | (112) |
Parabiosis | BMDM | HSC source of blood monocytes is replaced with modified/labeled HSCs | Constant influx of donor cells No myeloablationrequired No time consuming crossing into genetic disease models |
Technically challengingLow chimerism | (39) |
(b) Genetic lineage tracing models | |||||
Ccr2RFP/wt; Cx3cr1GFP/wt |
Monocytes (red) MG (green) |
Differential labeling of Cx3cr1hi: Ccr2neg MG (green) and of Cx3cr1lo:Ccr2hi monocytes (red) |
MG and monocytes contain reporter for labeling | Recruitment to the brain leads to increased Cx3cr1 levels in monocyte-derived macrophages Ccr2 expression is downregulated in monocyte-derived macrophage upon differentiation |
(114, 115) |
Flt3-Cre | Monocytes and HSC-derived monocyte precursors | Label/modification induced in Flt3+ monocyte precursors | Useful for lineage tracing of myeloid precursors Useful complementary approach to MG restricted lineage tracing |
Cre expression or transmittance restricted to male mice | (118) |
Cx3cr1-CreER | MG | Recombination is induced in all Cx3cr1+ cells upon tamoxifen pulse. Long-living MG retain the label/modification. While monocytes vanish and are replenished from precursors that were generated after Cre recombination in response to the tamoxifen pulse | Long-term labeling/modification is restricted to MG | Spontaneous modification reported in one model Low recombination in mMF (40–50%) |
(42) |
Sall1-CreER | MG | Label/modification induced in Sall1+ MG | Sall1 expression is stable also in response to different stimuli | Targeting of non-hematopoietic cells in the liver, heart and kidney | (119) |
(c) Cell-type restricted marker expression | |||||
CD45 | MGlo BMDMhi |
MG display lower surface expression | No requirement for combination of several markers | Activated in MG upregulate CD45 BMDM in brain malignancies downregulate CD45 |
(112, 113, 120) |
Tmem119P2ry12Siglech | MGhi BMDMlo |
MG show high expression | Applicable for mouse and human | Downregulation in MG during activation BMDM in GBM show increased expression |
(58, 94, 112) |
Sall1 | MGhi BMDMlo |
MG show high expression | Applicable for mouse and human Stable expression level at different activation levels |
Low expression found on non-leukocytes in the liver, heart, and kidney | (119) |
Itga4/Cd49d | MGlo BMDMhi |
BMDM show high expression | Applicable for mouse and human Stable expression level at different activation levels |
Expression found on T cells | (112) |
BMT, bone marrow transplantation; TBI, total body irradiation; HPI, head protected irradiation; BMDM, bone marrow-derived macrophage; HSC, hematopoietic stem cell; MG, microglia; BM, bone marrow; CNS, central nervous system.